Journal List > J Rheum Dis > v.26(1) > 1122086

Hwang, Ahn, Lee, Koh, and Cha: Rheumatoid Factor Positivity is Associated with Lower Bone Mass in Korean Male Health Examinees without Clinically Apparent Arthritis

Abstract

Objective

This cross-sectional study aimed to investigate the association between rheumatoid factor (RF) positivity and bone mineral density (BMD) in male Korean subjects without any history of joint disease.

Methods

Of 84,344 males who had under-gone a comprehensive health checkup program in 2012, 1,390 male health examinees were recruited, whose BMD and RF results were available. A RF titer ≥20 IU/mL was considered positive. BMD was measured at lumbar spine (L1∼ L4) or hip (femoral neck and total hip) by dual-energy X-ray absorptiometry.

Results

The association between RF positivity and BMD was assessed by multiple linear regression analysis. The mean age was 52.7±10.9 years (range 19∼88 years), and RF was detected in 64 subjects (4.6%). Demographics and laboratory data were not different between RF-positive and -negative subjects except hepatitis B surface antigen (HBsAg), which was more frequently seen in RF-positive subjects (15.6% vs. 4.3%, p=0.001). RF-positive subjects had significantly lower BMD compared to RF-negative subjects in lumbar spine but not in total hip regardless of the existence of HBsAg (1.17±0.16 g/cm2 vs. 1.10±0.18 g/cm2, p=0.002 in total subjects; 1.17±0.16 g/cm2 vs. 1.10±0.18 g/cm2, p=0.004 in HBsAg-negative subjects). After adjusting for multiple confounders, RF positivity was negatively associated with lumbar spine BMD (B=−0.088 and standard error=0.035, p=0.011).

Conclusion

Our results show that the presence of RF could have an unfavorable impact on bone density in apparently normal males. Additional studies to elucidate the osteoimmunological mechanism of rheumatoid factor are warranted.

REFERENCES

1. Pietschmann P, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of osteoporosis: a mini-review. Gerontology. 2016; 62:128–37.
crossref
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7:292–304.
crossref
3. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244–54.
crossref
4. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995; 34(Suppl 2):74–8.
crossref
5. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007; 46:342–9.
crossref
6. Pye SR, Adams JE, Ward KA, Bunn DK, Symmons DP, O'Neill TW. Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. Rheumatology (Oxford). 2010; 49:1943–8.
crossref
7. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis. 2007; 66:1508–12.
8. Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016; 18:226.
crossref
9. Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther. 2006; 8:R64.
10. Seeling M, Hillenhoff U, David JP, Schett G, Tuckermann J, Lux A, et al. Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A. 2013; 110:10729–34.
crossref
11. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012; 122:1791–802.
crossref
12. Johnson PM, Faulk WP. Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis. Clin Immunol Immunopathol. 1976; 6:414–30.
crossref
13. Shim CN, Hwang JW, Lee J, Koh EM, Cha HS, Ahn JK. Prevalence of rheumatoid factor and parameters associated with rheumatoid factor positivity in Korean health screening subjects and subjects with hepatitis B surface antigen. Mod Rheumatol. 2012; 22:885–91.
crossref
14. Shin YS, Choi JH, Nahm DH, Park HS, Cho JH, Suh CH. Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. Yonsei Med J. 2005; 46:464–70.
crossref
15. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol. 2014; 63:2679–86.
crossref
16. Zhang Y, Chang Y, Ryu S, Cho J, Lee WY, Rhee EJ, et al. Thyroid hormones and mortality risk in euthyroid individuals: the Kangbuk Samsung health study. J Clin Endocrinol Metab. 2014; 99:2467–76.
crossref
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–12.
crossref
18. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9:1137–41.
crossref
19. Soltys AI, Axford JS, Sutton BJ. Rheumatoid factors: where are we now? Ann Rheum Dis. 1997; 56:285–6.
crossref
20. Hwang J, Song JU, Ahn JK. Decline of pulmonary function is associated with the presence of rheumatoid factor in Korean health screening subjects without clinically apparent lung disease: a cross-sectional study. Medicine (Baltimore). 2016; 95:e3668.
21. Litwin SD, Singer JM. Studies of the incidence and significance of anti-gamma globulin factors in the aging. Arthritis Rheum. 1965; 8:538–50.
crossref
22. Watanabe K, Ohkubo Y, Funahashi Y, Nishimaki T, Moritoh T, Kasukawa R, et al. An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol. 1991; 10:31–7.
23. Lee SI, Yoo WH, Yun HJ, Kim DS, Lee HS, Choi SI, et al. Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection. Clin Rheumatol. 2007; 26:1079–82.
crossref
24. Cacoub P, Saadoun D, Bourlière M, Khiri H, Martineau A, Benhamou Y, et al. Hepatitis B virus genotypes and extra-hepatic manifestations. J Hepatol. 2005; 43:764–70.
crossref
25. Baeg MK, Yoon SK, Ko SH, Han KD, Choi HJ, Bae SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.
26. el-Khoury GY, Larson RK, Kathol MH, Berbaum KS, Furst DE. Seronegative and seropositive rheumatoid arthritis: radiographic differences. Radiology. 1988; 168:517–20.
crossref
27. Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum. 1976; 4:299–326.
crossref
28. Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, et al. Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun. 2015; 6:6637.
crossref
29. Mócsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A. 2004; 101:6158–63.
30. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005; 115:2914–23.
crossref
31. Falkenburg WJJ, von Richthofen HJ, Rispens T. On the origin of rheumatoid factors: insights from analyses of variable region sequences. Semin Arthritis Rheum. 2018 Jun 24; [Epub].DOI: DOI: 10.1016/j.semarthrit.2018.06.006.
crossref
32. Seeman E, Bianchi G, Adami S, Kanis J, Khosla S, Orwoll E. Osteoporosis in men–consensus is premature. Calcif Tissue Int. 2004; 75:120–2.
crossref
33. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 148:680–4.
crossref
34. Rissanen A, Heliövaara M, Aromaa A. Overweight and anthropometric changes in adulthood: a prospective study of 17,000 Finns. Int J Obes. 1988; 12:391–401.
35. Jiang Y, Zhang Y, Jin M, Gu Z, Pei Y, Meng P. Aged-related changes in body composition and association between body composition with bone mass density by body mass index in Chinese Han men over 50-year-old. PLoS One. 2015; 10:e0130400.
crossref

Figure 1.
Selection of subjects. BMD: bone mineral density, RF: rheumatoid factor.
jrd-26-31f1.tif
Figure 2.
Mean BMD and the proportion of low bone mass in lumbar spine along RF titers. (A) and (C) drawn for total subjects, and (B) and (D) for HBsAg-negative subjects. (A, B) RF titers were grouped into four categories, and each rhombus dot represents the mean estimated value (±95% CI) of lumbar BMD in the corresponding RF titer group. The imaginary connecting line between the dots demonstrates the decreasing tendency of BMD as the RF titers increase on one-way ANOVA testing (p=0.015 in A) and p=0.027 in B, respectively). (C, D) Each column represents the percentage of subjects with osteopenia (dark gray) and osteoporosis (light gray). Across the four groups, low bone mass frequency increases as RF titers increase (p for trend <0.001, both). BMD: bone mineral density, RF: rheumatoid factor, HBsAg: hepatitis B surface antigen, CI: confidence intervals.
jrd-26-31f2.tif
Table 1.
General characteristics by RF positivity in men (n=1,390)
  RF(−)(n=1,326) RF(+)(n=64) p-value
Age (yr) 52.7±10.9 55.0±10.7 0.093
Body mass index (kg/m2) 24.3±2.9 24.1±2.7 0.654
Obesity (≥30.0 kg/m2) 43 (3.2) 3 (4.7) 0.639
Current smoker (n=1,093) 394 (37.6) 20 (43.5) 0.665
Pack-years of smoking (n=1,063) 16.5±16.7 17.6±15.1 0.421
Alcohol intake (g/wk) (n=1,235) 30.2±43.9 27.8±41.2 0.777
Vigorous exercise (times/wk) (n=1,275) 1.27±1.9 0.88±1.6 0.092
Hypertension 316 (23.8) 9 (14.1) 0.098
Coronary artery disease 42 (3.2) 4 (6.2) 0.158
Fasting glucose (mg/dL) 98.6±14.7 97.3±14.0 0.487
Total cholesterol (mg/dL) 200.8±35.3 198.3±37.6 0.580
High density lipoprotein cholesterol (mg/dL) 52.9±13.9 53.8±14.4 0.579
Calcium (mg/dL) 9.4±0.3 9.4±0.4 0.787
Phosphorus (mg/dL) 3.4±0.4 3.4±0.5 0.455
Total vitamin D (mg/dL) 19.3±7.9 21.1±9.3 0.202
Uric acid (mg/dL) 5.9±1.2 6.0±1.3 0.633
HBsAg(+) 57 (4.3) 10 (15.6) 0.001
HCV Ab(+) (n=1,389) 6 (0.5) 0 1.000
eGFR (mL/min/1.73 m2) 87.5±20.0 84.3±15.5 0.118
CRP (mg/dL) 0.06 (0.02∼0.12) 0.08 (0.02∼ 0.19) 0.229
RF titer (IU/mL) 8.00 (4.95∼9.70) 34.2 (26.3∼77.2) <0.001

Values are presented as mean±standard deviation, number of subjects with percentages or median (interquartile range). RF: rheumatoid factor, HBsAg: hepatitis B virus surface antigen, HCV Ab: antibody against hepatitis C virus, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein. p-values were determined by Chi-square test for categorical variables, and Student's t-test or Mann-Whitney U-test which was for skewed continuous variables.

Table 2.
Bone mineral density values in total subjects
Variable Lumbar spine Variable Total hip
RF(−)(n=1,140) RF(+)(n=54) p-value RF(−)(n=249) RF(+)(n=12) p-value
BMD (g/cm2) 1.17±0.16 1.10±0.18 0.002 BMD (g/cm2) 0.97±0.15 0.94±0.23 0.537
(n=1,194)*       (n=261)*      
T-score (n=1,194)* −0.05±1.33 −0.64±1.52 0.009 T-score (n=261)* 0.17±1.19 −0.07±1.76 0.116
Category based on     <0.001 Category based on     0.683
spine T-score       total hip T-score      
(n=1,386)*       (n=307)*      
Normal 1,043 (78.9) 47 (73.4)   Normal 246 (83.4) 9 (75.0)  
Osteopenia 241 (18.2) 9 (14.1)   Osteopenia 47 (15.9) 3 (25.0)  
Osteoporosis 38 (2.9) 8 (12.5)   Osteoporosis 2 (0.7) 0  

Values are presented as mean±standard deviation or number of subjects with percentages. RF: rheumatoid factor, HBsAg: hepatitis B surface antigen, BMD: bone mineral density.

* The discrepancy of the numbers was due to the missing values between the L1∼ L4 BMD results and the category, and the category was determined by the lowest T-score. p-values were determined by Chi-square test for categorical variables, and Student's t-test or Mann-Whitney U-test for skewed continuous variables.

Table 3.
Bone mineral density values in subjects without HBsAg*
Variable Lumbar spine Variable Total hip
RF(−)(n=1,090) RF(+)(n=54) p-value RF(−)(n=240) RF(+)(n=10) p-value
BMD (g/cm2) 1.17±0.16 1.10±0.18 0.004 BMD (g/cm2) 0.97±0.15 0.96±0.24 0.922
(n=1,135)       (n=250)      
T-score (n=1,135) −0.06±1.32 −0.64±1.47 0.004 T-score (n=250) 0.17±1.19 −0.15±1.85 0.951
Category based on     0.026 Category based on     0.769
spine T-score       total hip T-score      
(n=1,319)       (n=262)      
Normal 1,002 (79.2) 39 (72.2)   Normal 215 (85.0) 7 (77.8)  
Osteopenia 227 (17.9) 9 (16.7)   Osteopenia 36 (14.2) 2 (22.2)  
Osteoporosis 36 (2.8) 6 (11.1)   Osteoporosis 2 (0.8) 0  

Values are presented asmean±standard deviation or number of subjects with percentages. RF: rheumatoid factor, HBsAg: hepatitis B surface antigen, BMD: bone mineral density. p-values were determined by Chi-square test for categorical variables, and Student's t-test or Mann-Whitney U-test for skewed continuous variables.

* This analysis was performed on HBsAg-negative subjects.

The discrepancy of the numbers was due to the missing values between the L1∼ L4 BMD results and the category, and the category was determined by the lowest T-score.

Table 4.
Multiple linear regression analysis of the association between the RF positivity and lumbar spine BMD*
BMD (g/cm2) B SE p-value R2
Model 1 −0.065 0.023 0.005 0.101
Model 2 −0.069 0.028 0.014 0.084
Model 3 −0.088 0.035 0.011 0.147

Model 1: adjusted for age, body mass index. Model 2: as for Model 1 plus: alcohol intake (g/week), smoking (pack-years), history of hypertension, and history of coronary artery disease. Model 3: as for Model 2 plus: fasting glucose, alanine aminotransferase, estimated glomerular filtration rate, uric acid, triglyceride, high density lipoprotein, homocysteine, ferritin, total vitamin D, and serum concentration of calcium and phosphorus. RF: rheumatoid factor, BMD: bone mineral density, B: unstandardized coefficient means the degree of change in lumbar spine BMD values (g/cm2) along the presence of RF, SE: standard error, R2: coefficient of multiple determination.

* This analysis was performed on HBsAg-negative subjects.

Supplementary Table 1.
Correlation between variables of model 2 in multiple regression analysis for the association of RF positivity with the lumbar spine BMD
Variable L1∼L4 BMD Age BMI Alcohol intake (g/wk) Smoking (pack-years) History of hypertension History of coronary artery disease HBsAg RF
L1∼L4 BMD Age 1.000 −0.023 (0.253) 1.000              
BMI 0.265 (<0.001) −0.058 (0.044) 1.000            
Alcohol intake (g/wk) 0.063 (0.031) −0.097 (0.002) 0.071 (0.019) 1.000          
Smoking (pack-years) 0.017 (0.313) 0.279 (<0.001) 0.066 (0.027) 0.096 (0.002) 1.000        
History of hypertension 0.037 (0.142) 0.319 (<0.001) 0.186 (<.001) 0.044 (0.100) 0.086 (0.006) 1.000      
History of coronary artery disease −0.002 (0.480) 0.134 (<0.001) 0.011 (0.375) 0.009 (0.396) 0.065 (0.029) 0.131(<0.001) 1.000    
HBsAg 0.026 (0.223) −0.027 (0.212) 0.019 (0.293) −0.035 (0.152) − −0.053 (0.061) − −0.044 (0.099) 0.034 (0.162) 1.000  
RF −0.078 (0.011) 0.037 (0.139) −0.033 (0.165) −0.001 (0.491) 0.020 (0.280) − −0.025 (0.236) 0.037 (0.142) 0.101 (0.001) 1.000

Values represent correlation coefficient (p-value). RF: rheumatoid factor, BMD: bone mineral density, BMI: body mass index, HBsAg: hepatitis B virus surface antigen.

TOOLS
Similar articles